MENU
+Compare
SBIO
ETF ticker: NYSE ARCA
AS OF
Feb 21 closing price
Price
$32.68
Change
+$0.08 (+0.25%)
Net Assets
98.7M

SBIO stock forecast, quote, news & analysis

Category: @Health
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for SBIO with price predictions
Feb 20, 2025

SBIO sees its Stochastic Oscillator climbs out of oversold territory

On February 14, 2025, the Stochastic Oscillator for SBIO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SBIO's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on January 22, 2025. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in of 317 cases, the price rose further within the following month. The odds of a continued upward trend are .

SBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SBIO as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 50-day moving average for SBIO moved below the 200-day moving average on January 28, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SBIO entered a downward trend on January 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 2B. The market cap for tickers in the group ranges from 56.16M to 16.31B. SMMT holds the highest valuation in this group at 16.31B. The lowest valued company is RPHM at 56.16M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 22%. For the same ETF, the average monthly price growth was 107%, and the average quarterly price growth was 153%. ALLO experienced the highest price growth at 60%, while RCUS experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was -13%. For the same stocks of the ETF, the average monthly volume growth was -12% and the average quarterly volume growth was 64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 80
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 81
Seasonality Score: -51 (-100 ... +100)
View a ticker or compare two or three
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com